Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-015532
Filing Date
2024-11-13
Accepted
2024-11-13 16:19:00
Documents
91
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q adap-20240930x10q.htm   iXBRL 10-Q 2113270
2 EX-10.1 adap-20240930xex10d1.htm EX-10.1 92421
3 EX-31.1 adap-20240930xex31d1.htm EX-31.1 9828
4 EX-31.2 adap-20240930xex31d2.htm EX-31.2 10571
5 EX-32.1 adap-20240930xex32d1.htm EX-32.1 6142
6 EX-32.2 adap-20240930xex32d2.htm EX-32.2 6124
7 GRAPHIC adap-20240930x10q002.jpg GRAPHIC 59521
  Complete submission text file 0001558370-24-015532.txt   9414065

Data Files

Seq Description Document Type Size
8 EX-101.SCH adap-20240930.xsd EX-101.SCH 60816
9 EX-101.CAL adap-20240930_cal.xml EX-101.CAL 81195
10 EX-101.DEF adap-20240930_def.xml EX-101.DEF 238906
11 EX-101.LAB adap-20240930_lab.xml EX-101.LAB 507938
12 EX-101.PRE adap-20240930_pre.xml EX-101.PRE 386318
94 EXTRACTED XBRL INSTANCE DOCUMENT adap-20240930x10q_htm.xml XML 1728832
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37368 | Film No.: 241454571
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)